Crude | Mutually adjusted | ||||||
---|---|---|---|---|---|---|---|
No. of patients/event | HR (95% CI) | P value | P overall | HR (95% CI) | P value | P overall | |
Tumour subtype | |||||||
Lum A | 118/83 | 1.00 | 1.00 | ||||
Lum B | 119/79 | 1.04 (0.76–1.41) | 0.827 | 1.11 (0.80–1.53) | 0.534 | ||
HER2/ER neg | 31/23 | 1.26 (0.79–2.01) | 0.325 | 1.54 (0.93–2.54) | 0.096 | ||
HER2 Lum | 38/19 | 0.76 (0.46–1.26) | 0.292 | 0.73 (0.43–1.25) | 0.254 | ||
Triple negative | 46/42 | 3.33 (2.27–4.86) | < 0.001 | < 0.001 | 2.95 (1.85–4.70) | < 0.001 | < 0.001 |
Age at metastasis, years | |||||||
< 50 | 50/32 | 1.00 | 1.00 | ||||
50–60 | 46/26 | 0.90 (0.54–1.51) | 0.694 | 1.02 (0.60–1.75) | 0.933 | ||
60–70 | 103/77 | 1.02 (0.67–1.54) | 0.935 | 0.99 (0.65–1.53) | 0.972 | ||
70–80 | 91/58 | 0.95 (0.62–1.47) | 0.830 | 1.12 (0.71–1.76) | 0.619 | ||
80+ | 62/53 | 2.17 (1.40–3.37) | 0.001 | < 0.001 | 3.40 (2.12–5.47) | < 0.001 | < 0.001 |
No. of metastatic sites at M1 | |||||||
1 | 158/99 | 1.00 | 1.00 | ||||
2 | 105/76 | 1.19 (0.88–1.61) | 0.247 | 1.39 (1.00–1.92) | 0.051 | ||
3+ | 89/71 | 1.71 (1.26–2.33) | 0.001 | 0.003 | 1.98 (1.36–2.89) | < 0.001 | 0.002 |
Dominating site of disease at M1 dx | |||||||
Bone | 105/63 | 1.00 | 1.00 | ||||
Soft tissue | 13/12 | 2.06 (1.11–3.83) | 0.022 | 1.24 (0.64–2.40) | 0.533 | ||
Visceral | 234/171 | 1.48 (1.11–1.98) | 0.007 | < 0.001 | 1.11 (0.78–1.57) | 0.560 | 0.755 |
Time since primary diagnosis, months | |||||||
0–3 | 80/50 | 1.00 | 1.00 | ||||
3–12 | 21/12 | 1.04 (0.55–1.95) | 0.910 | 1.14 (0.59–2.20) | 0.692 | ||
12–36 | 68/53 | 2.02 (1.37–2.98) | < 0.001 | 1.77 (1.12–2.80) | 0.015 | ||
36–60 | 40/29 | 1.57 (0.99–2.48) | 0.054 | 1.59 (0.99–2.54) | 0.054 | ||
60+ | 143/102 | 1.17 (0.83–1.64) | 0.376 | 0.004 | 1.19 (0.83–1.70) | 0.345 | 0.101 |
Year at M1 diagnosis | |||||||
2009–2011 | 150/131 | 1.00 | 1.00 | ||||
2012–2014 | 136/84 | 0.80 (0.60–1.06) | 0.124 | 0.82 (0.61–1.10) | 0.189 | ||
2015–2016 | 66/31 | 1.33 (0.88–2.02) | 0.178 | 0.055 | 1.42 (0.92–2.19) | 0.112 | 0.056 |